Jasper Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.1, beating the estimate of USD -0.3102.

EBIT: As of FY2026 Q2, the actual value is USD -9.125 M.

Financial Overview (Jasper Therapeutics, Inc.)

Cash and Cash Equivalents

Cash and cash equivalents for Jasper Therapeutics, Inc. totaled $7,314 thousand as of June 30, 2026, a decrease from $28,692 thousand as of December 31, 2025.

Operating Expenses (Three Months Ended June 30, 2026)

Research and development expense was $5,135 thousand, a decrease from $21,196 thousand for the same period in 2025. General and administrative expense was $4,072 thousand, down from $5,880 thousand for the same period in 2025. Total operating expenses were $9,207 thousand, a reduction from $27,076 thousand in the prior year period. Loss from operations was - $9,207 thousand, compared to - $27,076 thousand in the prior year period.

Operating Expenses (Six Months Ended June 30, 2026)

Research and development expense was $10,949 thousand, decreasing from $37,353 thousand for the same period in 2025. General and administrative expense was $9,210 thousand, a decrease from $11,525 thousand for the same period in 2025. Total operating expenses were $20,159 thousand, down from $48,878 thousand in the prior year period. Loss from operations was - $20,159 thousand, compared to - $48,878 thousand in the prior year period.

Other Income and Net Loss (Three Months Ended June 30, 2026)

Interest income was $82 thousand. The change in fair value of warrant liability was $3,980 thousand. Other income (expense), net was $2,385 thousand. Total other income, net, amounted to $6,447 thousand. Net loss and comprehensive loss was - $2,760 thousand, an improvement from - $26,723 thousand for the same period in 2025.

Other Income and Net Loss (Six Months Ended June 30, 2026)

Interest income was $246 thousand. The change in fair value of warrant liability was $13,620 thousand. Other income (expense), net was $2,359 thousand. Total other income, net, amounted to $16,225 thousand. Net loss and comprehensive loss was - $3,934 thousand, an improvement from - $47,964 thousand for the same period in 2025.

Non-Cash Stock Based Compensation Expense (Three Months Ended June 30, 2026)

Research and development included $185 thousand, and general and administrative included $579 thousand. Total non-cash stock based compensation expense was $764 thousand, down from $1,817 thousand for the same period in 2025.

Non-Cash Stock Based Compensation Expense (Six Months Ended June 30, 2026)

Research and development included $406 thousand, and general and administrative included $781 thousand. Total non-cash stock based compensation expense was $1,187 thousand, down from $3,628 thousand for the same period in 2025.

Balance Sheet Highlights (as of June 30, 2026, in thousands)

Total assets were $11,802, comprising current assets of $11,571, property and equipment, net of $60, operating lease right-of-use assets of $128, restricted cash, non-current of $0, and other non-current assets of $43. Total liabilities were $10,389, including current liabilities of $7,845, warrant liability of $2,544, and other non-current liabilities of $0. Total stockholders’ equity was $1,413, consisting of common stock of $3, additional paid-in capital of $322,014, and an accumulated deficit of - $320,604.

Operational Metrics and Recent Corporate Updates

On July 16, 2026, Jasper Therapeutics, Inc. completed the acquisition of Kira Pharmaceuticals in an all-stock transaction. Concurrently, the company completed a private placement, generating total gross proceeds of approximately $132 million through the sale of non-voting convertible preferred stock. The combined company is advancing KP-104, Briquilimab, and KP-701 as its pipeline candidates.

Outlook / Guidance

Jasper Therapeutics, Inc. anticipates having sufficient capital to fund planned operations through the second half of 2028, supported by the recent $132 million financing. The company plans to advance KP-104 development, progress briquilimab towards a potential Biologics License Application (BLA), and commence first-in-human studies for KP-701. Interim data from Stage 1 of the Phase 2 basket trial for KP-104 in rare renal indications is expected in the fourth quarter of 2026, with next steps for development in PNH to be announced in the first half of 2027.